Ongoing Monitoring. As required under the State Contract, United shall perform ongoing monitoring (announced or unannounced) of services rendered by Subcontractor under the Agreement and shall perform periodic formal reviews of Subcontractor according to a schedule established by the State, consistent with industry standards or State managed care organization laws and regulations or LDH requirements under the State Contract. As a result of such monitoring activities, United shall identify to Subcontractor any deficiencies or areas for improvement mandated under the State Contract and Subcontractor and United shall take appropriate corrective action. Subcontractor shall comply with any corrective action plan initiated by United and/or required by the Department. In addition, Subcontractor shall monitor and report the quality of services delivered under the Agreement and initiate a pla n of correction where necessary to improve quality of care, in accordance with that level of care which is recognized as acceptable professional practice in the respective community in which United and Subcontractor practice and/or the performance standards established by LDH in the State Contract and LDH-issued guides.
Ongoing Monitoring. The college reserves the right to remotely, while onsite, and locally monitor student owned and college based devices on an ongoing basis. Students found to be breaching the conditions of ICT Policies will be issued consequences. Students may be called up at any time by ICT, Sub-School or Principal Class staff to have their device checked for compliance with the college ICT Policies.
Ongoing Monitoring. Ongoing monitoring includes all activities related to implementing and maintaining the child’s comprehensive health care plan. The child’s assigned HCC is responsible for all ongoing monitoring activities.
Ongoing Monitoring. Ongoing monitoring by FPS and the Shippers Group ensures that the pipeline liquids delivered by the Shippers Group meet the agreed specification and are free from non-specification liquids/materials which could damage any part of the pipeline system or downstream facilities, or result in off-specification products, or that may prejudice health, safety, security or environmental performance.
Ongoing Monitoring. NSI may make visits as required to monitor the competence and effectiveness of your consultants in providing a professional service that satisfies both the terms and spirit of this ACP agreement.
Ongoing Monitoring. On an annual basis, at Landlord’s request, Tenant shall provide Landlord with reasonable evidence of its then current plans, if any, to undertake investigations to identify the presence, release, or potential for any release of Hazardous Materials, mold or conditions conducive to mold, in, on, or about the Leased Property, including but not limited to radon testing, asbestos surveys, soil, groundwater and air sampling, and tightness testing of underground storage tank systems. At Landlord’s request, Tenant shall participate in discussions with Landlord regarding such plans and the implementation thereof; provided, however, that Tenant shall not be required hereby to take any particular action suggested by Landlord. The obligations of this §5.2.3 shall not serve to limit any of Tenant’s other obligations under this Lease.
Ongoing Monitoring. Summit Place will request that the fingerprints taken for the purpose of conducting criminal background checks be registered with any rap back system maintained to provide ongoing status notifications to the school of any criminal history reported on individuals whose fingerprints are registered in the system.
Ongoing Monitoring. Licensor may enact such reasonable policies, programs, and requirements as it deems appropriate to document that requirements relating to maintenance, aesthetics, RF Emissions, and other requirements are being met, provided such policies, programs, and requirements are non-discriminatory, competitively neutral, and otherwise consistent with applicable Law.
Ongoing Monitoring. An increase in plasma creatinine has been observed with dronedarone 400mg twice daily in healthy subjects and in patients. This increase occurs early after treatment initiation and reaches a plateau after 7 days. If an increase in creatininemia is observed, this value should be used as the new reference baseline taking into account that this may be expected with dronedarone. An increase in creatininemia should not necessarily lead to the discontinuation of treatment with ACE-inhibitors or Angiotensin II Receptor Antagonists (AIIRAs). Side Effects System organ class Very Common ( 1/10) Common ( 1/100 to <1/10) Uncommon ( 1/1,000 to <1/100) Rare ( 1/10,000 to <1/1,000) Nervous system disorders Dysgeusia Ageusia Cardiac disorders Bradycardia Gastrointestinal disorders Diarrhoea Vomiting Nausea Abdominal pains Dyspepsia Skin and subcutaneous tissue disorders Rashes (including generalised, macular, maculo-papular) Pruritus Erythemas (including erythema and rash erythematous) Eczema Photosensitivity reaction Dermatitis allergic Dermatitis General disorders and administration site conditions Fatigue Asthenia Respiratory, thoracic and mediastinal disorders Interstitial lung disease including pneumonitis and pulmonary fibrosis Drug Interactions Amiodarone, disopyramide, clarithromycin, telithromycin, erythromycin, rifampicin, St. Xxxxx Wort, tricyclic antidepressants, carbamazepine, phenytoin, ketoconazole, itraconazole, posaconazole, voriconazole, antipsychotics that prolong QT interval, phenothiazines, ritonavir, phenobarbital, beta-blockers, nifedipine, diltiazem, verapamil, digoxin, grapefruit juice, simvastatin, sirolimus and tacrolimus. See current BNF for more details. References BNF 62 September 2011 xxxx://xxx.xxx/bnf/bnf/current/206568.htm?q=Dronedarone&t=search&ss=text&p=1#_hit <accessed 28.10.10> NICE Technology Appraisal 197 xxxx://xxx.xxxx.xxx.xx/nicemedia/live/13115/50471/50471.pdf <accessed 28.10.10> Summary of Product Characteristics-Dronedarone xxxx://xxx.xxxxxxxxx.xxx.xx/EMC/medicine/22894/SPC/Multaq+400mg+tablets/ <accessed 28.10.10> Medicines and Healthcare products Regulatory Agency. Drug Safety Update. October 2011 vol 5, issue 3: A1 Review Date December 2012 This ESCA should be read in conjunction with the Summary of Product Characteristics (SPC) and the current version of the BNF
Ongoing Monitoring. During the first year of treatment, the patient should be assessed at least every 3 months for: • Signs and symptoms of: o somnolence and sedation o hypotension o bradycardia • weight increase /risk of obesity It is recommended clinical judgment be exercised during this period. 6 monthly monitoring should follow thereafter, with more frequent monitoring following any dose adjustments Contraindications Hypersensitivity to guanfacine or to any of the excipients. Intuniv contains lactose. Patients with rare hereditary problems of galactose intolerance, the Xxxx lactase deficiency or glucose-galactose malabsorption should not take this medicinal product. Special warnings and precautions for use Hypotension, bradycardia and syncope Intuniv can cause syncope, hypotension and bradycardia. Syncope may involve risks of falls or accidents, which could result in serious harm. Prior to initiation of treatment, patient's cardiovascular status including heart rate and blood pressure parameters, family history of sudden cardiac death /unexplained death, should be assessed to identify patients at increased risk of hypotension, bradycardia, and QT-prolongation /risk of arrhythmia. Monitoring of heart rate and blood pressure parameters should continue on a weekly basis during dose titration and stabilisation and at least every 3 months for the first year, taking into consideration clinical judgement. 6 monthly monitoring should follow thereafter, with more frequent monitoring following any dose adjustment. Caution is advised when treating patients with Intuniv who have a history of hypotension, heart block, bradycardia, or cardiovascular disease, or who have a history of syncope or a condition that may predispose them to syncope, such as hypotension, orthostatic hypotension, bradycardia, or dehydration. Caution is also advised when treating patients with Intuniv who are being treated concomitantly with antihypertensives or other medicinal products that can reduce blood pressure or heart rate or increase the risk of syncope. Patients should be advised to drink plenty of fluid. QTc interval In phase II-III randomised double-blind monotherapy studies respective increases in QTc interval prolongation that exceeded change from baseline greater than >60 ms Xxxxxxxxxx-correction and Bazett-correction were 0 (0.0%) and 2 (0.3%) among placebo and 1 (0.1%) and 1 (0.1%) among Intuniv patients. The clinical relevance of this finding is uncertain. Guanfacine should be prescribed with ca...
